ABSTRACT Research in the United States has shown that youth mentoring is a promising strategy for increasing self-esteem and school connectedness in at-risk youth. There has been little confirmation of those findings internationally. The current study evaluates the impact of mentoring by trained university students on children's self-esteem and school connectedness compared to schoolmates not involved in the program. Mentor-UP is a school- and community-based weekly mentoring program implemented in northern Italy over a period of seven months. Participants (209 students – 34 in the experimental group and 175 in the comparison group – aged between 11 and 13, 56% male, 27% immigrants) reported their levels of self-esteem and school connectedness at the beginning and at the end of the program. Results showed a significant increase in mentees' self-esteem compared to the control group, while the difference in school-connectedness was nonsignificant. The findings support the effectiveness of Mentor-UP in nurturing youth's self-esteem.

RESUMEN La investigación en EE.UU. ha demostrado que la mentoría juvenil es una estrategia prometedora para aumentar la autoestima y la conexión escolar en jóvenes en situación de riesgo. Sin embargo, ha habido escasa confirmación de estos hallazgos a nivel internacional. El estudio actual evalúa el impacto de la mentoría por parte de estudiantes universitarios capacitados en autoestima y conexión escolar de los niños en comparación con los compañeros de escuela que no participaron en el programa. Mentor-UP es un programa de mentoría semanal llevado a cabo en la escuela y la comunidad que se implementó en el norte de Italia durante un período de siete meses. Los participantes (209 estudiantes, 34 en el grupo experimental y 175 en el grupo de comparación de edades comprendidas entre 11 y 13 años, 56% hombres, 27% inmigrantes) informaron de su nivel de autoestima y conexión escolar al principio y al final del programa. Los resultados mostraron un aumento significativo en la autoestima de los niños mentorizados en comparación con el grupo de control, mientras que la diferencia en la conexión escolar no fue significativa. Los hallazgos respaldan la efectividad de Mentor-UP para fomentar la autoestima de los jóvenes.

Abstract The isodecyl neopentanoate is an ingredient used in the cosmetic industry to prepare a nipple fissure balm. We report on 12 newborns that showed elevated C5-acylcarnitine levels upon newborn screening following treatment with balm. The first 3 neonates were immediately recalled for confirmatory tests and resulted negative for both isovaleric acidemia and short/branched chain acyl-CoA dehydrogenase deficiency. In the other 9 cases, the immediate recall was avoided by applying a new second-tier test able to confirm the presence of pivaloylcarnitine. The concentration of C5-acylcarnitine was measured in the days following the suspension of balm application. Abnormal concentrations of C5-acylcarnitine did not seem to be associated with free carnitine deficiency, probably due to the short time of exposure. A direct correlation between balm ingestion and the elevation in pivaloylcarnitine has been demonstrated in 10 adult volunteers. The commercial balm containing a pivalic acid derivative is causal of false-positive results during newborn screening, and it could have the potential to cause secondary carnitine deficiency when used chronically.

BACKGROUND: An epidemic of asbestos-related disease is ongoing in most industrialized countries, mainly attributable to past occupational exposure but partly due to environmental exposure. In this perspective, the incidence of pleural mesothelioma close to a former asbestos-cement plant in a national contaminated site was estimated. METHODS: The census-tracts interested by atmospheric dispersion of facilities in the contaminated site were identified. Two subareas with different estimated environmental asbestos impact were distinguished. An ecological study at micro-geographic level was performed. The standardized incidence ratios (SIR) for study area and the two subareas, in comparison with region and municipality were computed. The standardized incidence rate ratio (IRR) between the two subareas was computed. RESULTS: Mesothelioma incidence in the study area was increased: 46 cases were observed with respect to 22.23 expected (SIR: 2.02). The increase was confirmed in analysis considering only the subjects without an occupationally exposure to asbestos: 19 cases among men (SIR = 2.48; 95% CI: 1.49-3.88); 11 case among women (SIR = 1.34; 95% CI: 0.67-2.40). The IRR between the two subareas is less than one in overall population considering all age-classes and of 3 fold (IRR = 3.14, 95% CI: 0.65-9.17) in the age-classes below 55 years. CONCLUSIONS: The findings indicate an increased incidence of pleural mesothelioma in the neighbourhood of asbestos-cement plant, and a possible etiological contribution of asbestos environmental exposure in detected risks.

O oncogene RET/PTC foi isolado há quase 20 anos atrás. Durante esses anos de pesquisa várias questões foram solucionadas. Na verdade, já foi demonstrado que: a) o RET/PTC é um evento precoce no processo da carcinogênese da tiróide e tem um papel crítico na geração do carcinoma papilífero; b) a ativação do RET/PTC está restrita essencialmente ao histotipo papilar e aos tumores de Hürthle; c) sua incidência aumenta após a exposição à radiação. Entretanto, algumas questões permanecem ainda sem uma resposta final: a) qual é a real freqüência de ativação do RET/PTC? Provavelmente em torno de 20%, mas este número ainda é questionável; b) quais outras modificações gênicas são necessárias para transformar uma célula tiroidiana que possui oncogene RET/PTC no fenotipo maligno?; e c) existe alguma correlação entre a ativação do RET/PTC e parametros clínicos? Esperamos que essas questões sejam solucionadas em futuro próximo.

The RET/PTC oncogene has been isolated almost twenty years ago. During these years, the research has given a final answer to several questions. In fact, it has been demonstrated that: a) RET/PTC is an early event in the process of thyroid carcinogenesis and has a critical role in the generation of the papillary carcinoma; b) RET/PTC activation is essentially restricted to the papillary histotype and to the Hürthle thyroid tumors; c) its incidence increases after exposure to radiations. However, some questions have not found a final answer yet: a) which is the real frequency of RET/PTC activation? Likely it is around 20%, but this point is still questionable; b) which other gene modifications are required to lead a thyroid cell carrying a RET/PTC oncogene to the malignant phenotype?, and c) is there any correlation between RET/PTC activation and clinical parameters? We hope that these questions will have a clear answer in the near future.

Esta revisão focaliza as "novas drogas" que estão sendo desenvolvidas para o tratamento do câncer de tiróide. O câncer de tiróide está freqüentemente associado à ativação específica de quinases protéicas (RET, BRAF) e lipídicas [PI(3)K]. Há uma boa evidência de que essas lesões genéticas são eventos causativos de iniciação e progressão do câncer de tiróide. Assim sendo, novos compostos capazes de atuar nestas quinases podem ser úteis no tratamento do câncer de tiróide. A capacidade deste procedimento pode ser constatada pelos exemplos dos inibidores de BCR-ABL, c-KIT e EGFR no tratamento da leucemia mielóide crônica (LMC), dos tumores do estroma gastrointestinal (GIST) e carcinoma de células não pequenas do pulmão (NSCLC).

This review is focused on "new drugs" that might be developed for thyroid cancer treatment. Thyroid cancer is frequently associated to the activation of specific protein (RET, BRAF) and lipid [PI(3)K] kinases. There is good evidence that these genetic lesions are causative events in thyroid cancer initiation or progression. Therefore, novel compounds able to target these kinases might be useful for thyroid cancer treatment. The power of this approach is witnessed by the examples of BCR-ABL, c-KIT and EGFR inhibitors in the treatment of chronic myelogenous leukemia (CML), gastro-intestinal stromal tumors (GIST) and non-small cell lung carcinoma (NSCLC).